Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations

BACKGROUND: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Combination therapies with first-generation EGFR-TKIs and bevacizumab have been reported to prolong progression-free survival (PFS). However, there are few data on the combination of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Lung Cancer Res
Main Authors: Ko, Ryo, Shukuya, Takehito, Imamura, Chiyo K., Tokito, Takaaki, Shimada, Naoko, Koyama, Ryo, Yamada, Kazuhiko, Ishii, Hidenobu, Azuma, Koichi, Takahashi, Kazuhisa
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7867760/
https://ncbi.nlm.nih.gov/pubmed/33569303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-824
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados